New analysis supporting effect of Diamyd® diabetes vaccine to be presented at scientific conference on October 13
STOCKHOLM, September 23, 2021 / PRNewswire / – New Analysis Shows Effect of Diamyd Diabetes Vaccine® (GAD-alum) in reducing the time a patient has high blood sugar, has been selected to be presented at The International Society of Pediatric and Adolescent Diabetes (ISPAD) conference, to be held this year from October 13-15. . The analysis is based on continuous glucose monitoring (CGM) data and will be presented by the professor Johnny ludvigsson, principal investigator of the DIAGNODE-2 clinical trial.
The analysis shows that people with type 1 diabetes who carry the HLA DR3-DQ2 gene, 15 months after the start of the study, measured a significantly shorter time with high blood sugar (unadjusted p-value 0, 0043) and much longer with normal blood sugar (unadjusted p-value 0.0075) after treatment with Diamyd® than subjects treated with placebo. The presentation will be made on October 13 by the teacher Johnny ludvigsson and is titled “GAD-Alum intralymphatic (Diamyd®) improves hyperglycemia and glycemic control in type 1 diabetic patients with HLA DR3-DQ2 – Exploratory analysis of continuous glucose monitoring data from the Phase IIb clinical trial DIAGNODE-2 “. Full results will be submitted. for publication in a scientific journal later this year.
The new results confirm that the effect of the diabetes vaccine in preserving endogenous insulin production also leads to better blood sugar control. Previously reported results of a large-scale meta-analysis based on over 600 people who participated in four randomized, placebo-controlled clinical trials with Diamyd® show a significant positive effect of the diabetes vaccine both in maintaining endogenous insulin production capacity and in reducing blood glucose levels measured as HbA1c in individuals with the HLA DR3-DQ2 haplotype.
At ISPAD, the design of the next Phase 3 DIAGNODE-3 trial will also be presented, in the form of an electronic poster, by Ulf Hannelius, CEO of Diamyd Medical. Hannelius will also be making the same presentation at the American Society of Human Genetics (ASHG, October 18-22).
As previously announced, Ulf Hannelius will present a summary of the Diamyd results® meta-analysis at the EASD Diabetes Conference October 1, 2021. The EASD conference will be held virtually on September 27 – October 1, 2021.
About Diamyd Medical
Diamyd Medical develops precision medicine therapies for type 1 diabetes. The Diamyd diabetes vaccine® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results were shown in a large group of genetically predefined patients in a large-scale meta-analysis as well as in the European Phase IIb trial of the Company DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults. with recently diagnosed type 1 diabetes. Preparations for a confirmatory phase III trial in the United States and Europe are underway, to begin recruiting patients later in 2021. A vaccine manufacturing plant is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd®. Diamyd Medical is also developing GABA-based investigational drug Remygen® as therapy for the regeneration of endogenous insulin production and for improving the hormonal response to hypoglycemia. Remygen on the initiative of an investigator® a clinical trial in patients living with type 1 diabetes for more than five years is underway at Uppsala University Hospital. Diamyd Medical is a major shareholder of the stem cell company NextCell Pharma AB.
Diamyd Medical’s B share is traded on the Nasdaq First North Growth Market under the symbol DMYD B. FNCA Sweden AB is the authorized adviser of the company; phone: +46 8-528 00 399, e-mail: [email protected]
For more information, please contact:
Ulf Hannelius, President and CEO
Telephone: +46 736 35 42 41
Email: [email protected]
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/diamyd-medical-ab/r/a-new-analysis-that-supports-the-effect-of-the-diabetes-vaccine-diamyd–will-be-presented-at -a-science, c3420705
The following files are available for download:
SOURCE Diamyd Medical AB